AMP-activated protein kinase alleviates extracellular matrix accumulation in high glucose-induced renal fibroblasts through mTOR signaling pathway

Cellular Physiology and Biochemistry

Volumn 35, Issue 1, 2015, Pages 191-200

  Luo, Xia ^a   Deng, Lingyan ^a   Lamsal, Laxmi Pangeni ^a   Xu, Wenjuan ^a   Xiang, Cheng ^a   Cheng, Liming ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

AMPK; Diabetic nephropathy; Extracellular matrix; mTOR

Indexed keywords

ACETYL COENZYME A CARBOXYLASE; COLLAGEN TYPE 4; GLUCOSE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; INITIATION FACTOR 4E BINDING PROTEIN 1; MAMMALIAN TARGET OF RAPAMYCIN; PARVOVIRUS VECTOR; THREONINE; AMP-ACTIVATED PROTEIN KINASE ALPHA1 PROTEIN, RAT; TARGET OF RAPAMYCIN KINASE;

ADENO ASSOCIATED VIRUS; ARTICLE; CELL CULTURE; CONTROLLED STUDY; DIABETIC NEPHROPATHY; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; EXTRACELLULAR MATRIX; FIBROBLAST; IN VITRO STUDY; IN VIVO STUDY; INTRACELLULAR SIGNALING; KIDNEY FIBROSIS; KIDNEY INTERSTITIUM CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; RENAL INTERSTITIAL FIBROBLAST; RENAL PROTECTION; SIGNAL TRANSDUCTION; WESTERN BLOTTING; ADENOVIRIDAE; ANIMAL; CELL LINE; CYTOLOGY; DRUG EFFECTS; GENETICS; METABOLISM; MUTATION; PHOSPHORYLATION; RAT;

ACETYL-COA CARBOXYLASE; ADENOVIRIDAE; AMP-ACTIVATED PROTEIN KINASES; ANIMALS; CELL LINE; COLLAGEN TYPE IV; EXTRACELLULAR MATRIX; FIBROBLASTS; GLUCOSE; MUTATION; PHOSPHORYLATION; RATS; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES;

EID: 84921350773     PISSN: 10158987     EISSN: 14219778     Source Type: Journal    
DOI: 10.1159/000369687     Document Type: Article

References (40)

1. Papale M, Di Paolo S, Magistroni R, Lamacchia O, Di Palma AM, De Mattia A, Rocchetti MT, Furci L, Pasquali S, De Cosmo S, Cignarelli M, Gesualdo L: Urine proteome analysis may allow noninvasive differential diagnosis of diabetic nephropathy. Diabetes care 2010;33:2409-2415.
2. Chuang LY, Guh JY: Extracellular signals and intracellular pathways in diabetic nephropathy. Nephrology 2001;6:165-172.
3. Liu Y: Cellular and molecular mechanisms of renal fibrosis. Nat Rev Nephrol 2011;7:684-696.
4. Shiohira S, Yoshida T, Sugiura H, Nishida M, Nitta K, Tsuchiya K: Sphingosine-1-phosphate acts as a key molecule in the direct mediation of renal fibrosis. Physiol Rep 2013;1:e00172.
5. Jim B, Santos J, Spath F, Cijiang He J: Biomarkers of diabetic nephropathy, the present and the future. Curr Diabetes Rev 2012;8:317-328.
6. Morita M, Uchigata Y, Hanai K, Ogawa Y, Iwamoto Y: Association of urinary type iv collagen with gfr decline in young patients with type 1 diabetes. Am J Kidney Dis 2011;58:915-920.
7. Araki S, Haneda M, Koya D, Isshiki K, Kume S, Sugimoto T, Kawai H, Nishio Y, Kashiwagi A, Uzu T, Maegawa H: Association between urinary type iv collagen level and deterioration of renal function in type 2 diabetic patients without overt proteinuria. Diabetes care 2010;33:1805-1810.
8. Cornu M, Albert V, Hall MN: Mtor in aging, metabolism, and cancer. Curr Opin Genet Dev 2013;23:53-62.
9. Dazert E, Hall MN: Mtor signaling in disease. Curr Opin Cell Biol 2011;23:744-755.
10. Lloberas N, Cruzado JM, Franquesa M, Herrero-Fresneda I, Torras J, Alperovich G, Rama I, Vidal A, Grinyo JM: Mammalian target of rapamycin pathway blockade slows progression of diabetic kidney disease in rats. J Am Soc Nephrol 2006;17:1395-1404.
11. Novalic Z, van der Wal AM, Leonhard WN, Koehl G, Breuning MH, Geissler EK, de Heer E, Peters DJ: Dose-dependent effects of sirolimus on mtor signaling and polycystic kidney disease. J Am Soc Nephrol 2012;23:842-853.
12. Perico N, Antiga L, Caroli A, Ruggenenti P, Fasolini G, Cafaro M, Ondei P, Rubis N, Diadei O, Gherardi G, Prandini S, Panozo A, Bravo RF, Carminati S, De Leon FR, Gaspari F, Cortinovis M, Motterlini N, Ene- Iordache B, Remuzzi A, Remuzzi G: Sirolimus therapy to halt the progression of adpkd. J Am Soc Nephrol 2010;21:1031-1040.
13. Qin S, Taglienti M, Nauli SM, Contrino L, Takakura A, Zhou J, Kreidberg JA: Failure to ubiquitinate c-met leads to hyperactivation of mtor signaling in a mouse model of autosomal dominant polycystic kidney disease. J Clin Invest 2010;120:3617-3628.
14. Weimbs T: Polycystic kidney disease and renal injury repair: Common pathways, fluid flow, and the function of polycystin-1. Am J Physiol Renal Physiol 2007;293:F1423-1432.
15. Habib SL, Yadav M, Tizani S, Bhandari B, Valente AJ: Tuberin inhibits production of the matrix protein fibronectin in diabetes. J Am Soc Nephrol 2012;23:1652-1662.
16. Shegogue D, Trojanowska M: Mammalian target of rapamycin positively regulates collagen type i production via a phosphatidylinositol 3-kinase-independent pathway. J Biol Chem 2004;279:23166-23175.
17. Sola-Villa D, Camacho M, Sola R, Soler M, Diaz JM, Vila L: Il-1beta induces vegf, independently of pge2 induction, mainly through the pi3-k/mtor pathway in renal mesangial cells. Kidney Int 2006;70:1935-1941.
18. Vollenbroker B, George B, Wolfgart M, Saleem MA, Pavenstadt H, Weide T: Mtor regulates expression of slit diaphragm proteins and cytoskeleton structure in podocytes. Am J Physiol Renal Physiol 2009;296:F418- 426.
19. Wang S, Wilkes MC, Leof EB, Hirschberg R: Noncanonical tgf-beta pathways, mtorc1 and abl, in renal interstitial fibrogenesis. Am J Physiol Renal Physiol 2010;298:F142-149.
20. Chen JK, Chen J, Neilson EG, Harris RC: Role of mammalian target of rapamycin signaling in compensatory renal hypertrophy. J Am Soc Nephrol 2005;16:1384-1391.
21. Bolster DR, Crozier SJ, Kimball SR, Jefferson LS: Amp-activated protein kinase suppresses protein synthesis in rat skeletal muscle through down-regulated mammalian target of rapamycin (mtor) signaling. J Biol Chem 2002;277:23977-23980.
22. Sataranatarajan K, Mariappan MM, Lee MJ, Feliers D, Choudhury GG, Barnes JL, Kasinath BS: Regulation of elongation phase of mrna translation in diabetic nephropathy: Amelioration by rapamycin. Am J Pathol 2007;171:1733-1742.
23. Jiang L, Xu L, Mao J, Li J, Fang L, Zhou Y, Liu W, He W, Zhao AZ, Yang J, Dai C: Rheb/mtorc1 signaling promotes kidney fibroblast activation and fibrosis. J Am Soc Nephrol 2013;24:1114-1126.
24. Lee MJ, Feliers D, Mariappan MM, Sataranatarajan K, Mahimainathan L, Musi N, Foretz M, Viollet B, Weinberg JM, Choudhury GG, Kasinath BS: A role for amp-activated protein kinase in diabetes-induced renal hypertrophy. Am J Physiol Renal Physiol 2007;292:F617-627.
25. Lee HJ, Mariappan MM, Feliers D, Cavaglieri RC, Sataranatarajan K, Abboud HE, Choudhury GG, Kasinath BS: Hydrogen sulfide inhibits high glucose-induced matrix protein synthesis by activating amp-activated protein kinase in renal epithelial cells. J Biol Chem 2012;287:4451-4461.
26. Lee MJ, Feliers D, Sataranatarajan K, Mariappan MM, Li M, Barnes JL, Choudhury GG, Kasinath BS: Resveratrol ameliorates high glucose-induced protein synthesis in glomerular epithelial cells. Cell Signal 2010;22:65-70.
27. Gorin Y, Block K, Hernandez J, Bhandari B, Wagner B, Barnes JL, Abboud HE: Nox4 nad(p)h oxidase mediates hypertrophy and fibronectin expression in the diabetic kidney. J Biol Chem 2005;280:39616-39626.
28. Mishra R, Cool BL, Laderoute KR, Foretz M, Viollet B, Simonson MS: Amp-activated protein kinase inhibits transforming growth factor-beta-induced smad3-dependent transcription and myofibroblast transdifferentiation. J Biol Chem 2008;283:10461-10469.
29. Satriano J, Sharma K, Blantz RC, Deng A: Induction of ampk activity corrects early pathophysiological alterations in the subtotal nephrectomy model of chronic kidney disease. Am J Physiol Renal Physiol 2013;305:F727-733.
30. Lee JH, Kim JH, Kim JS, Chang JW, Kim SB, Park JS, Lee SK: Amp-activated protein kinase inhibits tgf-beta-, angiotensin ii-, aldosterone-, high glucose-, and albumin-induced epithelial-mesenchymal transition. Am J Physiol Renal Physiol 2013;304:F686-697.
31. Chen KH, Hsu HH, Lee CC, Yen TH, Ko YC, Yang CW, Hung CC: The ampk agonist aicar inhibits tgf-beta1 induced activation of kidney myofibroblasts. PLoS One 2014;9:e106554.
32. Hardie DG: Ampk: A target for drugs and natural products with effects on both diabetes and cancer. Diabetes 2013;62:2164-2172.
33. Mason RM, Wahab NA: Extracellular matrix metabolism in diabetic nephropathy. J Am Soc Nephrol 2003;14:1358-1373.
34. Hardie DG: Amp-activated/snf1 protein kinases: Conserved guardians of cellular energy. Nat Rev Mol Cell Biol 2007;8:774-785.
35. Hardie DG, Ross FA, Hawley SA: Ampk: A nutrient and energy sensor that maintains energy homeostasis. Nat Rev Mol Cell Biol 2012;13:251-262.
36. Morales AI, Detaille D, Prieto M, Puente A, Briones E, Arevalo M, Leverve X, Lopez-Novoa JM, El-Mir MY: Metformin prevents experimental gentamicin-induced nephropathy by a mitochondria-dependent pathway. Kidney Int 2010;77:861-869.
37. Mount PF, Hill RE, Fraser SA, Levidiotis V, Katsis F, Kemp BE, Power DA: Acute renal ischemia rapidly activates the energy sensor ampk but does not increase phosphorylation of enos-ser1177. Am J Physiol Renal Physiol 2005;289:F1103-1115.
38. Takiar V, Nishio S, Seo-Mayer P, King JD, Jr., Li H, Zhang L, Karihaloo A, Hallows KR, Somlo S, Caplan MJ: Activating amp-activated protein kinase (ampk) slows renal cystogenesis. Proc Natl Acad Sci U S A 2011;108:2462-2467.
39. Mariappan MM: Signaling mechanisms in the regulation of renal matrix metabolism in diabetes. Exp Diabetes Res 2012;2012:749812.
40. Ikeda Y, Sato K, Pimentel DR, Sam F, Shaw RJ, Dyck JR, Walsh K: Cardiac-specific deletion of lkb1 leads to hypertrophy and dysfunction. J Biol Chem 2009;284:35839-35849.